Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon

Table 2 Summary of recommendation for interferon-free hepatitis C virus therapy in naïve patients without (a) and with (b) cirrhosis[65,66,90,91,94,115-126]

	SOF + RBV[65,66]	SOF + LDV[65,66]	PTV/r + OMB + DSV[65,66]	PTV/r + OMB[65,66]	SOF + SMV[65,66]	SOF + DCV[66]
	(SVR)	(SVR)	(SVR)	(SVR)	(SVR)	(SVR)
Without cirrhosis
Genotype 1a		8-12 wk	12 wk with RBV		12 wk without RBV	12 wk without RBV
		(93%-99%)	(95%-97%)		(93%-100%)	(95%-100%)
Genotype 1b		8-12 wk	12 wk without RBV		12 wk without RBV (93%-100%)	12 wk without RBV
		(93%-99%)	(98%-99%)			(95%-100%)
Genotype 2	12 wk
	(97%)
Genotype 3	24 wk					12 wk without RBV
	(94%)					(89-97%)
Genotype 4		12 wk		12 wk with RBV	12 wk without RBV	12 wk without RBV
		(95%)				(89%-97%)
Genotype 5 or 6		12 wk				12 wk without RBV
						(89%-97%)
With cirrhosis
Genotype 1a		12 wk without RBV (95%)	24 wk with RBV		12 wk without RBV	12 wk with or 24 wk without RBV
			(92%)		(93%)
Genotype 1b		12 wk without RBV	12 wk with RBV
			(96%)
Genotype 2	16-20 wk					12 wk without RBV
	(78%-83%)
Genotype 3	24 wk					24 wk with RBV
	(92%)
Genotype 4		12 wk with RBV or 24 wk without RBV		24 wk with RBV	12 wk without RBV	12 wk with RBV or 24 wk without RBV
Genotype 5 or 6		12 wk with RBV or 24 wk without RBV				12 wk with RBV or 24 wk without RBV

HCV: Hepatitis C virus; Peg: Pegylated interferon; RBV: Ribavirin; SOF: Sofosbuvir; SMV: Simeprevir; LDV: Ledipasvir; PTV: Paritaprevir; r: Ritonavir; OMB: Ombitasvir; DSV: Dasabuvir; DCV: Daclatasvir.